Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
REF<strong>ER</strong>ENCES<br />
1. Group EBCTC 1998 Tamoxifen for early breast cancer: an overview of the<br />
randomised trials. Lancet 351:1451-67<br />
2. Gradishar WJ 2004 Tamoxifen--what next? Oncologist 9:378-84<br />
3. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin<br />
WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-<br />
Chiu E, Ford L, Wolmark N 1998 Tamoxifen for prevention of breast cancer:<br />
report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J<br />
Natl Cancer Inst 90:1371-88.<br />
4. Osborne CK, Schiff R 2005 Aromatase inhibitors: future directions. J Steroid<br />
Biochem Mol Biol 95:183-7<br />
5. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M<br />
2003 Integration of signal transduction inhibitors with endocrine therapy: an<br />
approach to overcoming hormone resistance in breast cancer. Clin Cancer Res<br />
9:524S-32S<br />
6. Lonning PE 2004 Aromatase inhibitors in breast cancer. Endocr Relat Cancer<br />
11:179-89<br />
7. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud<br />
T 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen<br />
alone for adjuvant treatment of postmenopausal women with early breast cancer:<br />
first results of the ATAC randomised trial. Lancet 359:2131-9<br />
8. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione<br />
M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton<br />
41